FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * FROST PHILLIP MD ET AL 2. Issuer Name and Ticker or Trading Symbol Opko Health, Inc. [ OPK ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    __X__ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CEO & Chairman
(Last)         (First)         (Middle)
OPKO HEALTH, INC., 4400 BISCAYNE BLVD.
3. Date of Earliest Transaction (MM/DD/YYYY)
5/26/2020
(Street)
MIAMI, FL 33137
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                 3068951  D   
Common Stock  5/26/2020    P    50000  A $2.31  189721694  I  See Footnote (1)
Common Stock  5/26/2020    P    4850  A $2.335  189726544  I  See Footnote (1)
Common Stock  5/26/2020    P    5700  A $2.339  189732244  I  See Footnote (1)
Common Stock  5/26/2020    P    39450  A $2.34  189771694  I  See Footnote (1)
Common Stock  5/26/2020    P    341  A $2.345  189772035  I  See Footnote (1)
Common Stock  5/26/2020    P    22319  A $2.35  189794354  I  See Footnote (1)
Common Stock  5/26/2020    P    1000  A $2.3597  189795354  I  See Footnote (1)
Common Stock  5/26/2020    P    26340  A $2.36  189821694  I  See Footnote (1)
Common Stock  5/26/2020    P    300  A $2.3625  189821994  I  See Footnote (1)
Common Stock  5/26/2020    P    11776  A $2.365  189833770  I  See Footnote (1)
Common Stock  5/26/2020    P    9336  A $2.37  189843106  I  See Footnote (1)
Common Stock  5/26/2020    P    20541  A $2.375  189863647  I  See Footnote (1)
Common Stock  5/26/2020    P    700  A $2.379  189864347  I  See Footnote (1)
Common Stock  5/26/2020    P    44274  A $2.38  189908621  I  See Footnote (1)
Common Stock  5/26/2020    P    1430  A $2.385  189910051  I  See Footnote (1)
Common Stock  5/26/2020    P    11643  A $2.39  189921694  I  See Footnote (1)
Common Stock                 30127177  I  See Footnote (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
(2)  These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of five limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
FROST PHILLIP MD ET AL
OPKO HEALTH, INC.
4400 BISCAYNE BLVD.
MIAMI, FL 33137
X X CEO & Chairman
Frost Gamma Investments Trust
4400 BISCAYNE BLVD.
MIAMI, FL 33137

X


Signatures
Phillip Frost, M.D., Individually and as Trustee 5/27/2020
**Signature of Reporting Person Date
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Opko Health Charts.
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Opko Health Charts.